Overview

Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.
Phase:
Phase 2
Details
Lead Sponsor:
Institut BergoniƩ
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus